FDA approves label expansion for Shire’s HAE drug Cinryze
Shire has secured a label expansion from the US Food and Drug Administration (FDA) for its hereditary angioedema (HAE) therapy Cinryze to help prevent angioedema attacks in HAE-affected children, aged 6 years and older.
Leave a Reply
Want to join the discussion?Feel free to contribute!